BLFS Stock Overview
Develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BioLife Solutions, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.85 |
| 52 Week High | US$26.73 |
| 52 Week Low | US$8.92 |
| Beta | 1.85 |
| 11 Month Change | 7.53% |
| 3 Month Change | 19.73% |
| 1 Year Change | 103.86% |
| 33 Year Change | -55.71% |
| 5 Year Change | 27.15% |
| Change since IPO | -95.24% |
Recent News & Updates
Recent updates
Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
Aug 14
BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Jun 20A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Jun 05Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
May 14Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
May 13Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
May 11Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Mar 12BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price
Feb 19BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion
Dec 19Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term
Aug 17Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Aug 11Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
May 06Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?
Feb 22Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
Jan 10Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Dec 10BioLife: What The Future Holds
Oct 19BioLife Solutions COO Roderick de Greef to retire
Oct 03BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Sep 27BioLife Solutions GAAP EPS of -$1.71 misses by $1.50, revenue of $40.5M beats by $1.33M
Aug 09BioLife Solutions: Sell-Side Posture Overly Optimistic, Rate Neutral
Jul 29Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
Jun 15Shareholder Returns
| BLFS | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.1% | -0.2% | 0.6% |
| 1Y | 103.9% | 2.3% | 22.9% |
Return vs Industry: BLFS exceeded the US Life Sciences industry which returned 3.8% over the past year.
Return vs Market: BLFS exceeded the US Market which returned 24.9% over the past year.
Price Volatility
| BLFS volatility | |
|---|---|
| BLFS Average Weekly Movement | 7.8% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BLFS's share price has been volatile over the past 3 months.
Volatility Over Time: BLFS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 412 | Rod de Greef | www.biolifesolutions.com |
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
BioLife Solutions, Inc. Fundamentals Summary
| BLFS fundamental statistics | |
|---|---|
| Market cap | US$1.20b |
| Earnings (TTM) | -US$63.55m |
| Revenue (TTM) | US$139.96m |
8.5x
P/S Ratio-18.8x
P/E RatioIs BLFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLFS income statement (TTM) | |
|---|---|
| Revenue | US$139.96m |
| Cost of Revenue | US$89.11m |
| Gross Profit | US$50.85m |
| Other Expenses | US$114.40m |
| Earnings | -US$63.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.38 |
| Gross Margin | 36.33% |
| Net Profit Margin | -45.40% |
| Debt/Equity Ratio | 6.6% |
How did BLFS perform over the long term?
See historical performance and comparison